SCHEMBL6092352

SCHEMBL6092352

CC(CC(=O)Nc1ccc2nc(-c3nccs3)[nH]c2c1)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.53
RAB9A P51151 7/20 0.53
NPC1 O15118 5/20 0.53
HTT P42858 1/20 0.53
MAPT P10636 5/20 0.48
KDM4E B2RXH2 6/20 0.48
ALDH1A1 P00352 6/20 0.48
HPGD P15428 6/20 0.48
TP53 P04637 4/20 0.48
HSD17B10 Q99714 3/20 0.48
KLK7 P49862 1/20 0.48
RXFP1 Q9HBX9 1/20 0.46
MAPK1 P28482 2/20 0.46
POLB P06746 3/20 0.45
KMT2A Q03164 3/20 0.45
APAF1 O14727 2/20 0.45
PPARG P37231 1/20 0.45
RECQL P46063 1/20 0.45
SMAD3 P84022 1/20 0.45
PTK2B Q14289 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6092686 0.92 MAPT (0.51) SMN1; SMN2RAB9ANPC1HTTMAPT
SCHEMBL6092024 0.84 SMN1; SMN2 (0.51) SMN1; SMN2RAB9ANPC1HTTMAPT
SCHEMBL6093781 0.84 MAPT (0.53) SMN1; SMN2RAB9ANPC1HTTMAPT
SCHEMBL4367691 0.83 ALDH1A1 (0.48) SMN1; SMN2RAB9ANPC1HTTMAPT
SCHEMBL4372123 0.82 ALDH1A1 (0.49) SMN1; SMN2RAB9ANPC1HTTMAPT
SCHEMBL4368880 0.82 MMP2 (0.60) SMN1; SMN2RAB9ANPC1HTTMAPT
SCHEMBL6093689 0.82 MAPT (0.59) SMN1; SMN2RAB9ANPC1HTTMAPT
SCHEMBL4371979 0.81 METAP1 (0.55) SMN1; SMN2RAB9ANPC1HTTKDM4E
SCHEMBL4367716 0.81 METAP1 (0.55) SMN1; SMN2RAB9ANPC1HTTKDM4E
SCHEMBL4368621 0.81 METAP1 (0.55) SMN1; SMN2RAB9ANPC1HTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060036098-A1 Carbonylamino-benzimidazole derivatives as androgen receptor modulators MERCK SHARP & DOHME CORP. 2006-02-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060036098-A1 Carbonylamino-benzimidazole derivatives as androgen receptor modulators AR, SHBG, BRCA1 SMN1; SMN2 2413/4885RAB9A 4310/4885NPC1 3580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.